Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
72 studies found for:    Open Studies | "Conjunctivitis"
Show Display Options
Rank Status Study
1 Not yet recruiting Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Placebo
Condition: Adenoviral Conjunctivitis
Interventions: Drug: SHP640;   Drug: Placebo
2 Not yet recruiting Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Povidone-iodine (PVP-I) and Placebo
Condition: Adenoviral Conjunctivitis
Interventions: Drug: SHP640;   Drug: PVP-I 0.6%;   Drug: Placebo
3 Recruiting Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis
Condition: Bacterial Conjunctivitis
Interventions: Drug: Vancomycin 1.1%;   Drug: Placebo
4 Not yet recruiting Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo
Condition: Adenoviral Conjunctivitis
Interventions: Drug: SHP640;   Drug: PVP-I 0.6%;   Drug: Placebo
5 Recruiting A Study of ADX-102 in Subjects With Allergic Conjunctivitis
Condition: Conjunctivitis, Allergic
Interventions: Drug: ADX-102 Ophthalmic Drops (0.5%);   Drug: ADX-102 Ophthalmic Drops (0.1%);   Drug: Vehicle of ADX-102 Ophthalmic Drops
6 Recruiting Perforated Punctal Plugs for Treatment of Papillary Conjunctivitis in Otherwise Healthy Patients
Conditions: Epiphora;   Conjunctivitis
Interventions: Device: Perforated Punctal plugs;   Procedure: Crawford tube insertion;   Device: Crawford lacrimal tube
7 Recruiting Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea
Condition: Conjunctivitis, Allergic
Intervention: Drug: Alcaftadine Ophthalmic Solution 0.25%
8 Recruiting Reducing Adenoviral Patient Infected Days
Conditions: Conjunctivitis;   Adenoviral Conjunctivitis
Interventions: Drug: Betadine 5%;   Drug: Artificial Tears
9 Not yet recruiting Efficacy and Safety of Iota-Carrageenan Eye Drops (NCX-4240)
Condition: Adenoviral Conjunctivitis
Interventions: Drug: Iota-Carrageenan;   Drug: Carmellose
10 Recruiting A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis
Conditions: Keratoconjunctivitis Due to Adenovirus;   Viral Shedding
Interventions: Drug: Zirgan;   Drug: genteal gel
11 Recruiting Observational Study of Oralair® in Children 5-9 Years With Grass-pollen-induced Allergic Rhinitis With/Without Conjunctivitis
Condition: Allergy
Intervention: Drug: Oralair
12 Not yet recruiting A Multicenter Study to Evaluate Safety and Efficacy of Specific Immunotherapy With Modified Allergen Extracts
Conditions: Allergic Rhinitis;   Allergic Conjunctivitis
Interventions: Biological: modified allergen extract;   Biological: Placebo
13 Recruiting Seasonal Differences in Nasal Mucus Proteome and Impact of Immunotherapy
Condition: Allergic Rhinoconjunctivitis
Intervention: Biological: Immunotherapy
14 Recruiting Efficacy and Safety of LAIS® Mites Sublingual Tablets
Condition: Allergic Conditions
Intervention: Drug: LAIS®
15 Recruiting Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis
Condition: Hay Fever
Interventions: Biological: Placebo solution;   Biological: gpASIT+TM
16 Recruiting Topical Tacrolimus in Vernal Keratoconjunctivitis
Condition: Vernal Keratoconjunctivitis
Intervention: Drug: Topical tacrolimus
17 Not yet recruiting Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Mite Allergy
Conditions: Rhinitis;   Rhinoconjunctivitis
Interventions: Biological: MM09 Mannosylated 5.000 subcutaneous;   Biological: MM09 Mannosylated 10.000 subcutaneous;   Biological: MM09 Mannosylated 30.000 subcutaneous;   Biological: MM09 Mannosylated 50.000 subcutaneous;   Biological: MM09 Mannosylated 5.000 sublingual;   Biological: MM09 Mannosylated 10.000 sublingual;   Biological: MM09 Mannosylated 30.000 sublingual;   Biological: MM09 Mannosylated 50.000 sublingual;   Biological: Subcutaneous placebo;   Biological: Sublingual placebo
18 Not yet recruiting Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy
Conditions: Rhinitis;   Rhinoconjunctivitis
Interventions: Biological: MG56 Mannosylated 5.000 subcutaneous;   Biological: MG56 Mannosylated 10.000 subcutaneous;   Biological: MG56 Mannosylated 30.000 subcutaneous;   Biological: MG56 Mannosylated 50.000 subcutaneous;   Biological: MG56 Mannosylated 5.000 sublingual;   Biological: MG56 Mannosylated 10.000 sublingual;   Biological: MG56 Mannosylated 30.000 sublingual;   Biological: MG56 Mannosylated 50.000 sublingual;   Biological: Subcutaneous placebo;   Biological: Sublingual placebo
19 Recruiting Safety, Tolerability and Efficacy of the Depigmented Modified Allergen Extract of Two Mites in Subjects With Allergic Rhinitis or Rhinoconjunctivitis, With Controlled Allergic Asthma
Conditions: Rhinitis;   Rhinoconjunctivitis;   Asthma
Interventions: Biological: DP/MG/14-1;   Biological: DP/MG/14-2
20 Not yet recruiting Evaluation of Tolerability and Safety of "Allergovac Poliplus" in Polysensitized Patients With Rhinitis or Allergic Rhinoconjunctivitis With or Without Asthma: A Study in Daily Clinical Practice
Conditions: Allergic Rhinitis;   Rhinoconjunctivitis;   Asthma
Intervention: Biological: Allergovac Poliplus

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.